Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context

被引：2

作者：

Gullapalli, Sneha ^{[1
]}

Remon, Jordi ^{[2
]}

El Hendriks, Lizza ^{[3
]}

Lopes, Gilberto ^{[4
,5
]}

机构：

[1] Univ Miami, Jackson Mem Hosp, Div Pulm & Crit Care, Miami, FL 33136 USA

[2] HM Hosp, Hosp HM Delfos, Ct Integral Oncol Clara Campal HM CIOCC, Dept Med Oncol, Avinguda Vallcarca 151, Barcelona 08023, Spain

[3] Maastricht Univ, Sch Oncol & Dev Biol, Med Ctr +, Dept Pulm Dis GROW, Maastricht, Netherlands

[4] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Dept Med,Div Hematol, Miami, FL 33136 USA

[5] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Dept Med,Div Med Oncol, Miami, FL 33136 USA

来源：

ONCOTARGETS AND THERAPY | 2020年 / 13卷

基金：

美国国家卫生研究院;

关键词：

durvalumab; non-small cell lung cancer; PACIFIC; rechallenge; MYSTIC; PLATINUM-BASED CHEMOTHERAPY; STAGE-III NSCLC; CONSOLIDATION IMMUNOTHERAPY; CHEMORADIOTHERAPY REGIMEN; PEMBROLIZUMAB; NIVOLUMAB; OUTCOMES; EFFICACY; 1ST-LINE; SAFETY;

D O I：

10.2147/OTT.S259308

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Immune checkpoint inhibitors (ICIs) have transformed the therapeutic strategy and prognosis of advanced non-small cell lung cancer (NSCLC) patients. Nowadays, ICIs as monotherapy or in combination with chemotherapy are the standard of care treatment in advanced NSCLC, and in stage III, durvalumab (a programmed death ligand 1 inhibitor) is the unique drug approved as consolidation treatment after chemo-radiotherapy. This article reviews the pharmacological properties, clinical activity and safety of durvalumab as mono - therapy or in combination with chemotherapy or other ICIs in the therapeutic strategy of NSCLC patients.

引用

页码：6885 / 6896

页数：12

共 86 条

[1] Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer [J].

Aggarwal, Charu ;

Thompson, Jeffrey C. ;

Chien, Austin L. ;

Quinn, Katie J. ;

Hwang, Wei-Ting ;

Black, Taylor A. ;

Yee, Stephanie S. ;

Christensen, Theresa E. ;

LaRiviere, Michael J. ;

Silva, Benjamin A. ;

Banks, Kimberly C. ;

Nagy, Rebecca J. ;

Helman, Elena ;

Berman, Abigail T. ;

Ciunci, Christine A. ;

Singh, Aditi P. ;

Wasser, Jeffrey S. ;

Bauml, Joshua M. ;

Langer, Corey J. ;

Cohen, Roger B. ;

Carpenter, Erica L. .

CLINICAL CANCER RESEARCH, 2020, 26 (10) :2354-2361

[2] Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression [J].

Aguilar, E. J. ;

Ricciuti, B. ;

Gainor, J. F. ;

Kehl, K. L. ;

Kravets, S. ;

Dahlberg, S. ;

Nishino, M. ;

Sholl, L. M. ;

Adeni, A. ;

Subegdjo, S. ;

Khosrowjerdi, S. ;

Peterson, R. M. ;

Digumarthy, S. ;

Liu, C. ;

Sauter, J. ;

Rizvi, H. ;

Arbour, K. C. ;

Carter, B. W. ;

Heymach, J. V. ;

Altan, M. ;

Hellmann, M. D. ;

Awad, M. M. .

ANNALS OF ONCOLOGY, 2019, 30 (10) :1653-1659

[3]

[Anonymous], 2019, J CLIN ONCOL S

[4]

[Anonymous], 2017, ANN ONCOL, DOI DOI 10.1093/ANNONC/MDX380.002

[5]

[Anonymous], 2019, UPDATE PHASE 3 NEPTU

[6]

[Anonymous], 2018, P AM SOC CLIN ONCO S, DOI DOI 10.1200/JC0.2018.36.15_SUPPL.9002

[7] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Kurata, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

Carpeno, J. de Castro ;

Faivre-Finn, C. ;

Reck, M. ;

Vansteenkiste, J. ;

Spigel, D. R. ;

Wadsworth, C. ;

Melillo, G. ;

Taboada, M. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) :2342-2350

[8] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[9] Safety and antitumour activity of durvalumab plus tremelimumab in non-small-cell lung cancer: a multicentre, phase 1b study [J].

Antonia, Scott ;

Goldberg, Sarah B. ;

Balmanoukian, Ani ;

Chaft, Jamie E. ;

Sanborn, Rachel E. ;

Gupta, Ashok ;

Narwal, Rajesh ;

Steele, Keith ;

Gu, Yu ;

Karakunnel, Joyson J. ;

Rizvi, Naiyer A. .

LANCET ONCOLOGY, 2016, 17 (03) :299-308

[10] Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC [J].

Antonia, Scott J. ;

Balmanoukian, Ani ;

Brahmer, Julie ;

Ou, Sai-Hong I. ;

Hellmann, Matthew D. ;

Kim, Sang-We ;

Ahn, Myung-Ju ;

Kim, Dong-Wan ;

Gutierrez, Martin ;

Liu, Stephen V. ;

Schoffski, Patrick ;

Jaeger, Dirk ;

Jamal, Rahima ;

Jerusalem, Guy ;

Lutzky, Jose ;

Nemunaitis, John ;

Calabro, Luana ;

Weiss, Jared ;

Gadgeel, Shirish ;

Bhosle, Jaishree ;

Ascierto, Paolo A. ;

Rebelatto, Marlon C. ;

Narwal, Rajesh ;

Liang, Meina ;

Xiao, Feng ;

Antal, Joyce ;

Abdullah, Shaad ;

Angra, Natasha ;

Gupta, Ashok K. ;

Khleif, Samir N. ;

Segal, Neil H. .

JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) :1794-1806

← 1 2 3 4 5 6 7 8 9 →